Company intelligence / Profile preview
Sollievo Pharmaceuticals
San Juan Capistrano, California, United States
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
Sollievo Pharmaceuticals is developing Proviza, a proprietary intramuscular formulation of the benzodiazepine pro-drug avizafone, for rapid sedation of acutely agitated and aggressive patients. In animal studies, Proviza demonstrated a four-fold improvement in absorption rate and onset of sedation versus market-leading sedatives. As of April 2025, Proviza had not yet entered active clinical trials, but a New Drug Application (NDA) submission was anticipated in the first half of 2024.
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sollievo Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sollievo Pharmaceuticals.